{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:25:58Z","timestamp":1791822358642,"version":"4.3.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/ndt\/gfi253","type":"journal-article","created":{"date-parts":[[2005,11,12]],"date-time":"2005-11-12T01:13:32Z","timestamp":1131758012000},"page":"378-382","source":"Crossref","is-referenced-by-count":341,"title":["Update on adverse drug events associated with parenteral iron"],"prefix":"10.1093","volume":"21","author":[{"given":"Glenn M.","family":"Chertow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd","family":"Vaage-Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl","family":"Ahlm\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,11,11]]},"reference":[{"key":"key\n\t\t\t\t20171012192540_BIB1","doi-asserted-by":"crossref","unstructured":"NKF-K\/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis2001; 37 [1 Suppl 1]: S182\u2013S238","DOI":"10.1016\/S0272-6386(01)70008-X"},{"key":"key\n\t\t\t\t20171012192540_BIB2","doi-asserted-by":"crossref","unstructured":"Li S, Foley RN, Gilbertson DT, Liu J, Collins AJ. Clinical factors associated with achieving K\/DOQI hemoglobin targets in hemodialysis patients. Int Urol Nephrol2003; 35: 399\u2013405","DOI":"10.1023\/B:UROL.0000022951.17591.0b"},{"key":"key\n\t\t\t\t20171012192540_BIB3","doi-asserted-by":"crossref","unstructured":"Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant1998; 13: 82\u201388","DOI":"10.1093\/ndt\/13.1.82"},{"key":"key\n\t\t\t\t20171012192540_BIB4","doi-asserted-by":"crossref","unstructured":"Fishbane S. Safety in iron management. Am J Kidney Dis2003; 41 [Suppl 5]: 18\u201326","DOI":"10.1016\/S0272-6386(03)00373-1"},{"key":"key\n\t\t\t\t20171012192540_BIB5","doi-asserted-by":"crossref","unstructured":"McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran \u2013 a comparison of two products. Am J Nephrol2000; 20: 455\u2013462","DOI":"10.1159\/000046199"},{"key":"key\n\t\t\t\t20171012192540_BIB6","doi-asserted-by":"crossref","unstructured":"Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis2001; 37: 743\u2013749","DOI":"10.1016\/S0272-6386(01)80123-2"},{"key":"key\n\t\t\t\t20171012192540_BIB7","doi-asserted-by":"crossref","unstructured":"Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis1999; 33: 464\u2013470","DOI":"10.1016\/S0272-6386(99)70183-6"},{"key":"key\n\t\t\t\t20171012192540_BIB8","doi-asserted-by":"crossref","unstructured":"Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial2000; 13: 381\u2013384","DOI":"10.1046\/j.1525-139x.2000.00104.x"},{"key":"key\n\t\t\t\t20171012192540_BIB9","doi-asserted-by":"crossref","unstructured":"Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int2002; 61: 1830\u20131839","DOI":"10.1046\/j.1523-1755.2002.00314.x"},{"key":"key\n\t\t\t\t20171012192540_BIB10","doi-asserted-by":"crossref","unstructured":"Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant2004; 19: 1571\u20131575","DOI":"10.1093\/ndt\/gfh185"},{"key":"key\n\t\t\t\t20171012192540_BIB11","doi-asserted-by":"crossref","unstructured":"Fleiss JL. Confidence intervals for the odds ratio in case-control studies: the state of the art. J Chronic Dis1979; 32: 69\u201377","DOI":"10.1016\/0021-9681(79)90015-8"},{"key":"key\n\t\t\t\t20171012192540_BIB12","doi-asserted-by":"crossref","unstructured":"Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant2005; 20: 1443\u20131449","DOI":"10.1093\/ndt\/gfh820"},{"key":"key\n\t\t\t\t20171012192540_BIB13","doi-asserted-by":"crossref","unstructured":"Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int2004; 66: 144\u2013156","DOI":"10.1111\/j.1523-1755.2004.00716.x"},{"key":"key\n\t\t\t\t20171012192540_BIB14","doi-asserted-by":"crossref","unstructured":"Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int2004; 65: 2279\u20132289","DOI":"10.1111\/j.1523-1755.2004.00648.x"},{"key":"key\n\t\t\t\t20171012192540_BIB15","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis2001; 37: 564\u2013572","DOI":"10.1053\/ajkd.2001.22433"},{"key":"key\n\t\t\t\t20171012192540_BIB16","doi-asserted-by":"crossref","unstructured":"Pillon L, Piccoli A, Lowrie EG, Lazarus JM, Chertow GM. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int2004; 66: 1266\u20131271","DOI":"10.1111\/j.1523-1755.2004.00881.x"},{"key":"key\n\t\t\t\t20171012192540_BIB17","unstructured":"U.S. Renal Data System. USRDS 2004 Annual Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004"},{"key":"key\n\t\t\t\t20171012192540_BIB18","doi-asserted-by":"crossref","unstructured":"Ubel PA. Pricing Life: Why it's Time for Health Care Rationing. MIT Press, Cambridge, MA: 2000; 31\u201346","DOI":"10.7551\/mitpress\/5533.001.0001"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/2\/378\/5235395\/gfi253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T20:24:00Z","timestamp":1586550240000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/2\/378\/1850825\/Update-on-adverse-drug-events-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,11]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,11,11]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi253","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,11,11]]}}}